Sacituzumab Tirumotecan and Furmonertinib Phase 2 NSCLC Study
ClinicalTrials.gov Studies
Summary
NIH registered a Phase 2 clinical trial (NCT07548060) evaluating sacituzumab tirumotecan in combination with furmonertinib in patients with locally advanced or metastatic non-squamous non-small cell lung cancer who have progressed after EGFR-TKI and platinum-based chemotherapy. The single-arm study specifies conditions as NSCLC Stage IV with EGFR Gene Mutation. The trial was registered April 23, 2026.
“Efficacy and Safety of Sacituzumab Tirumotecan Combined with Furmonertinib in Patients with Locally Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy.”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
NIH added a new Phase 2 clinical trial registration to ClinicalTrials.gov under identifier NCT07548060. The study will assess the efficacy and safety of sacituzumab tirumotecan combined with furmonertinib in adult patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC Stage IV) harboring an EGFR Gene Mutation who have previously progressed after EGFR-TKI and platinum-based chemotherapy. No regulatory obligations or compliance deadlines are imposed by this registration document.
For pharmaceutical companies and clinical investigators, this registration signals an active Phase 2 clinical development pathway combining an ADC (sacituzumab tirumotecan) with an EGFR TKI (furmonertinib) in a defined patient population resistant to standard EGFR-TKI and chemotherapy regimens. Sponsors developing competing ADC or EGFR-inhibitor assets for EGFR-mutant NSCLC should monitor enrollment progress and emerging efficacy data from this trial.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy
Phase 2 NCT07548060 Kind: PHASE2 Apr 23, 2026
Abstract
Efficacy and Safety of Sacituzumab Tirumotecan Combined with Furmonertinib in Patients with Locally Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy.
Conditions: NSCLC Stage IV, EGFR Gene Mutation
Interventions: sacituzumab tirumotecan
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.